Stocklytics Platform
Celldex Therapeutics
CLDX60
$20.42arrow_drop_up1.48%$0.30
CLDX60

$20.42

arrow_drop_up1.48%

Analyst Forecast

no data available for Analyst Forecast

There's no data available for Analyst Forecast

Period: -

• Predicted: -

Analyst Ratings

no data available for Analyst Ratings

There's no data available for Analyst Ratings

Last updated: -

• Total: -

Celldex Therapeutics (CLDX) Stocklytics Forecast

Celldex Therapeutics Inc (CLDX) is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of various forms of cancer. With a strong pipeline and innovative approach to drug development, CLDX is poised to make a significant impact in the field of oncology.
Financial experts and analysts have been closely monitoring the performance of CLDX and making predictions about its future stock price. While no prediction is foolproof, there are some key indicators that suggest CLDX is a promising investment.
add Celldex Therapeutics to watchlist

Keep an eye on Celldex Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Celldex Therapeutics (CLDX) stock?

Analysts have set a target price of $67.96 for Celldex Therapeutics (CLDX), based on forecasts from 23 analysts. The predicted price range extends from a high of $90 to a low of $27. This represents a potential increase of up to 340.74% and a decrease of 32.22% from the current price of $20.42. These forecasts are as of 2021 Sep 13.
help

What are the analyst ratings for Celldex Therapeutics (CLDX) stock?

Currently, there are no analyst ratings available for Celldex Therapeutics (CLDX), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Celldex Therapeutics (CLDX) stock?

At present, there is no AI or machine-learning-based price prediction available for Celldex Therapeutics (CLDX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level